These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 25710838)

  • 21. Direct Reprogramming of Human Amniotic Fluid Stem Cells by OCT4 and Application in Repairing of Cerebral Ischemia Damage.
    Qin M; Chen R; Li H; Liang H; Xue Q; Li F; Chen Y; Zhang X
    Int J Biol Sci; 2016; 12(5):558-68. PubMed ID: 27019637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reprogramming of blood cells into induced pluripotent stem cells as a new cell source for cartilage repair.
    Li Y; Liu T; Van Halm-Lutterodt N; Chen J; Su Q; Hai Y
    Stem Cell Res Ther; 2016 Feb; 7():31. PubMed ID: 26883322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemically Induced Reprogramming of Somatic Cells to Pluripotent Stem Cells and Neural Cells.
    Biswas D; Jiang P
    Int J Mol Sci; 2016 Feb; 17(2):226. PubMed ID: 26861316
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 'Channeling' therapeutic discovery for epileptic encephalopathy through iPSC technologies.
    Simkin D; Ambrosi C; Marshall KA; Williams LA; Eisenberg J; Gharib M; Dempsey GT; George AL; McManus OB; Kiskinis E
    Trends Pharmacol Sci; 2022 May; 43(5):392-405. PubMed ID: 35427475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Temporal repression of endogenous pluripotency genes during reprogramming of porcine induced pluripotent stem cells.
    Hall VJ; Kristensen M; Rasmussen MA; Ujhelly O; Dinnyés A; Hyttel P
    Cell Reprogram; 2012 Jun; 14(3):204-16. PubMed ID: 22578162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Roadblocks to reprogramming, cleared.
    de Souza N
    Nat Methods; 2013 Nov; 10(11):1051. PubMed ID: 24344378
    [No Abstract]   [Full Text] [Related]  

  • 27. Integration-free reprogramming of human somatic cells to induced pluripotent stem cells (iPSCs) without viral vectors, recombinant DNA, and genetic modification.
    Heng BC; Fussenegger M
    Methods Mol Biol; 2014; 1151():75-94. PubMed ID: 24838880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanism of Induction: Induced Pluripotent Stem Cells (iPSCs).
    Singh VK; Kumar N; Kalsan M; Saini A; Chandra R
    J Stem Cells; 2015; 10(1):43-62. PubMed ID: 26665937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative study of human-induced pluripotent stem cells derived from bone marrow cells, hair keratinocytes, and skin fibroblasts.
    Streckfuss-Bömeke K; Wolf F; Azizian A; Stauske M; Tiburcy M; Wagner S; Hübscher D; Dressel R; Chen S; Jende J; Wulf G; Lorenz V; Schön MP; Maier LS; Zimmermann WH; Hasenfuss G; Guan K
    Eur Heart J; 2013 Sep; 34(33):2618-29. PubMed ID: 22798560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cellular reprogramming and cancer development.
    Semi K; Matsuda Y; Ohnishi K; Yamada Y
    Int J Cancer; 2013 Mar; 132(6):1240-8. PubMed ID: 23180619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential therapeutic applications of differentiated induced pluripotent stem cells (iPSCs) in the treatment of neurodegenerative diseases.
    Gao A; Peng Y; Deng Y; Qing H
    Neuroscience; 2013 Jan; 228():47-59. PubMed ID: 23069758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Divergent reprogramming routes lead to alternative stem-cell states.
    Tonge PD; Corso AJ; Monetti C; Hussein SM; Puri MC; Michael IP; Li M; Lee DS; Mar JC; Cloonan N; Wood DL; Gauthier ME; Korn O; Clancy JL; Preiss T; Grimmond SM; Shin JY; Seo JS; Wells CA; Rogers IM; Nagy A
    Nature; 2014 Dec; 516(7530):192-7. PubMed ID: 25503232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reprogramming and transdifferentiation shift the landscape of regenerative medicine.
    Guo J; Wang H; Hu X
    DNA Cell Biol; 2013 Oct; 32(10):565-72. PubMed ID: 23930590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms underlying the formation of induced pluripotent stem cells.
    González F; Huangfu D
    Wiley Interdiscip Rev Dev Biol; 2016; 5(1):39-65. PubMed ID: 26383234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induced Pluripotency and Gene Editing in Disease Modelling: Perspectives and Challenges.
    Seah YF; El Farran CA; Warrier T; Xu J; Loh YH
    Int J Mol Sci; 2015 Dec; 16(12):28614-34. PubMed ID: 26633382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stem cells: Close encounters with full potential.
    Loh KM; Lim B
    Nature; 2013 Oct; 502(7469):41-2. PubMed ID: 24048472
    [No Abstract]   [Full Text] [Related]  

  • 37. Human induced pluripotent stem cells in Parkinson's disease: A novel cell source of cell therapy and disease modeling.
    Li W; Chen S; Li JY
    Prog Neurobiol; 2015 Nov; 134():161-77. PubMed ID: 26408505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Generating induced pluripotent stem cell derived endothelial cells and induced endothelial cells for cardiovascular disease modelling and therapeutic angiogenesis.
    Clayton ZE; Sadeghipour S; Patel S
    Int J Cardiol; 2015 Oct; 197():116-22. PubMed ID: 26123569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modeling human neurological disorders with induced pluripotent stem cells.
    Imaizumi Y; Okano H
    J Neurochem; 2014 May; 129(3):388-99. PubMed ID: 24286589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The triumph of chemically enhanced cellular reprogramming: a patent review.
    Anwar MA; Kim S; Choi S
    Expert Opin Ther Pat; 2016; 26(2):265-80. PubMed ID: 26593376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.